Research Article
Evaluation of Quality of Life at Progression in Patients with Soft Tissue Sarcoma
Table 3
Adjusted mean values at baseline and progression stratified by treatment and histology.
| | Domain/time point | Eribulin | DAC | value | | Liposarcoma | Leiomyosarcoma | Liposarcoma | Leiomyosarcoma | Mean (SD)
BL
PD | Mean (SD)
BL
PD | Mean (SD)
BL
PD | Mean (SD)
BL
PD |
| | Global health score and functioning | | | | | | | Global Health Status | | | | | | | Baseline | 64.6 (24.40) | 65.5 (23.15) | 64.6 (20.93) | 65.1 (20.55) | — | | Progression | 61.3 (23.52) | 62.4 (23.33) | 57.5 (20.29) | 55.6 (22.42) | 0.008 | | Physical Functioning | | | | | | | Baseline | 73.2 (25.76) | 78.2 (21.12) | 76.8 (21.53) | 76.4 (19.87) | — | | Progression | 71.4 (24.33) | 74.0 (22.15) | 63.9 (28.93) | 66.4 (25.48) | 0.002 | | Role Functioning | | | | | | | Baseline | 69.8 (31.61) | 75.9 (27.18) | 75.0 (26.28) | 73.9 (25.89) | — | | Progression | 57.9 (36.63) | 67.4 (31.34) | 60.2 (29.82) | 58.2 (32.30) | 0.054 | | Emotional Functioning | | | | | | | Baseline | 73.1 (23.10) | 76.6 (21.05) | 73.0 (24.51) | 74.4 (21.88) | — | | Progression | 73.1 (27.33) | 71.2 (26.13) | 69.9 (23.50) | 69.2 (24.40) | 0.366 | | Cognitive Functioning | | | | | | | Baseline | 84.8 (19.26) | 84.4 (19.66) | 83.1 (21.83) | 84.2 (21.24) | — | | Progression | 82.4 (20.26) | 80.5 (23.94) | 77.6 (24.90) | 79.1 (24.82) | 0.338 | | Social Functioning | | | | | | | Baseline | 64.7 (33.52) | 74.8 (27.78) | 71.8 (27.69) | 74.0 (26.20) | — | | Progression | 62.3 (35.98) | 70.6 (26.87) | 63.2 (29.06) | 66.1 (28.96) | 0.282 | | Symptom scales | | | | | | | Fatigue | | | | | | | Baseline | 34.1 (27.44) | 30.1 (24.53) | 32.6 (25.98) | 31.7 (22.14) | — | | Progression | 39.2 (28.46) | 40.1 (25.61) | 43.5 (28.03) | 45.4 (28.58) | 0.067 | | Nausea and Vomiting | | | | | | | Baseline | 8.2 (17.30) | 7.2 (13.92) | 8.9 (18.00) | 7.8 (18.12) | — | | Progression | 7.2 (11.09) | 8.1 (15.70) | 12.9 (22.12) | 14.1 (19.85) | 0.001 | | Pain | | | | | | | Baseline | 28.3 (31.09) | 25.9 (26.77) | 31.9 (26.88) | 29.9 (29.03) | — | | Progression | 35.8 (30.03) | 34.2 (29.92) | 34.4 (24.86) | 40.3 (32.63) | 0.175 | | Dyspnea | | | | | | | Baseline | 16.9 (22.60) | 19.1 (25.91) | 19.2 (27.98) | 18.6 (23.77) | — | | Progression | 22.0 (25.27) | 22.3 (26.42) | 35.4 (33.62) | 24.6 (27.70) | 0.063 | | Insomnia | | | | | | | Baseline | 24.2 (29.64) | 26.8 (27.32) | 24.4 (28.71) | 29.0 (29.27) | — | | Progression | 30.8 (33.56) | 25.4 (30.65) | 28.6 (27.22) | 34.7 (29.67) | 0.035 | | Appetite Loss | | | | | | | Baseline | 16.9 (25.96) | 16.8 (25.68) | 18.3 (29.70) | 18.4 (28.18) | — | | Progression | 18.2 (24.95) | 20.0 (28.07) | 29.9 (32.09) | 29.3 (32.85) | 0.001 | | Constipation | | | | | | | Baseline | 19.8 (30.42) | 16.6 (23.30) | 17.4 (26.94) | 13.8 (22.36) | — | | Progression | 20.7 (25.51) | 20.2 (28.04) | 23.8 (27.22) | 22.5 (28.50) | 0.368 | | Diarrhea | | | | | | | Baseline | 10.6 (21.76) | 8.7 (19.03) | 12.2 (23.39) | 9.4 (20.99) | — | | Progression | 13.8 (18.98) | 13.2 (24.23) | 11.6 (25.05) | 9.9 (19.77) | 0.169 | | Financial Difficulties | | | | | | | Baseline | 26.1 (34.24) | 23.5 (32.19) | 25.4 (33.08) | 25.8 (31.99) | — | | Progression | 37.1 (42.70) | 27.3 (33.00) | 34.7 (33.99) | 27.2 (31.67) | 0.846 |
|
|
indicates values that are less than 0.05 and are considered statistically significant. DAC: dacarbazine.
|
